U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07332975) titled 'ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC' on Dec. 30, 2025.
Brief Summary: This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment.
Study Start Date: Jan. 31
Study Type: OBSERVATIONAL
Condition:
Triple Negative Breast Cancer
Recruitment Status: NOT_YET_RECRUITING
Sponsor: University of Pittsburgh
Information provided by (Responsible Party): Marija Balic, MD PhD, University of Pittsburgh
Disclaimer: Curated by HT Syndication....